Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1994-12-21
1997-06-17
Kight, John
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 23, 536 41, 53612313, A61K 3170
Patent
active
056397372
ABSTRACT:
Growth or metastasization of malignant tumors can be inhibited by administering to a patient in need thereof sufficient lactose to block crucial lectins on the affected organ so that the tumor cells cannot anchor to other locations in the body. Lactose can be administered alone, or in combination with conjugates of cytotoxic drugs. Preferably, lactose is conjugated to a cytotoxic substance so that the primary tumor is treated concurrently with prevention of metastasis. Additionally, by conjugating a cytotoxic drug to lactose, the cytotoxic drug is maintained in close proximity to the tumor because of the receptors on the tumor which bind the lactose (and therefore the cytotoxic agent bound thereto) to the tumor cells. By using a conjugate of lactose with a cytotoxic agent, one dose is generally sufficient to destroy the receptor sites on the tumor and prevent metastasis of the tumor while treating the tumor.
REFERENCES:
patent: 4337760 (1982-07-01), Rubin
patent: 4424348 (1984-01-01), Rubin
patent: 4481195 (1984-11-01), Rubin
patent: 4584368 (1986-04-01), Rubin
patent: 4812590 (1989-03-01), Saari
patent: 4946830 (1990-08-01), Pulverer et al.
patent: 5225542 (1993-07-01), Cramer et al.
patent: 5239062 (1993-08-01), Blattler et al.
patent: 5340803 (1994-08-01), Rubin
patent: 5395924 (1995-03-01), Blattler et al.
Smit et al., Melonoma Res., vol. 2(5-6), pp. 295-304, (1992).
Naish-Byfield et al., Melanoma Res., vol. 1(4), pp. 273-287, (1991).
Assaf et al., Planta Med., vol. 53(4), pp. 343-345, (1987).
Firon et al., Infect. Immun., vol. 55(2), pp. 472-476, (1987).
Lotan et al. Carbohydrate Research, vol. 213, pp. 47-57, (1991).
Nakamura et al. Medical Journal of Kiniki University, vol. 19(4), pp. 537-551, (1994).
Platt et al. J. Natl. Cancer Inst., vol. 84(6), pp. 438-442, (1992).
Database Chemabs, Chemical Abstracts Service, Columbus, Ohio, Naito, Albert T., "Substances Penetrating the Blood-Brain Barrier," JP A 05 339 148, AN=120:208571.
Database Medline, U.S. National Library of Medicine, Bethesda, Maryland AN=68362667 & Archiv Furgeschwulstforschung, vol. 29, No. 3, 1967, pp. 226-273, Tanneberger et al., "On the Value of Chloroquine in the Treatment of Malignant Tumor Diseases".
Avraham et al., "Lectin-Like Activities Associated with Human and Murine Neoplastic Cells," Cancer Research, vol. 41, Sep. 1981 MD US, pp. 3642-3647.
Kaneko et al. Chem. Pharm Bull. vol. 25 (9), pp. 2458-2460.
Baba et al. Gann vol. 69, pp. 283,284, (1978).
Co Enzyme Technology Ltd.
Kight John
Lee Howard C.
LandOfFree
Method and compositions for treating malignant tumors and inhibi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and compositions for treating malignant tumors and inhibi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and compositions for treating malignant tumors and inhibi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2157850